

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name **Antonello Pani, M.D.**
Address **Cagliari - Via Malpighi 10**
Telephone **0039 070 539 496 - 333 680 16 27**
Fax **0039 070 539 491**
E-mail **antonellopani@aob.it; antonello.pani@unica.it**

Nationality **Italian**

Date of birth **13 June 1957**
Place of work **ARNAS G. Brotzu
Nephrology and Dialysis Department
Piazza A. Ricchi – 1 (Cagliari-Italy)
University of Cagliari**

WORK EXPERIENCE

Full Professor in Nephrology – University of Cagliari (valid from 1/02/2022 to 10/01/2031).
Director of the Graduate School in Nephrology (2021)
Associate Professor at the Department of Medical Sciences and Health. University of Cagliari (Italy) - 2016.
Director Renal Department – ARNAS - G. Brotzu Hospital (2018).
Director Renal Unit - ARNAS G. Brotzu Hospital - Cagliari - from 2009.
Director of Department of Reproduction, Genitourinary, Diseases Kidney Transplant from 01/04/2018.

1993 - Research Fellow - Renal Unit del Guy's Hospital Medical Dental Schools di Londra

Visiting Physician at Azienda Ospedaliera S. Carlo Borromeo, Milan IT
Consultant in Nephrology, Azienda Ospedaliera G. Brotzu, Cagliari IT
2016 - Associate Professor at the Department of Medical Sciences and Health. University of Cagliari (Italy)

Visiting academic positions

Visiting Professor (Aging and the Kidney). The University of Virginia Charlottesville (Virginia), 20.11.2016.

Visiting Professor “Nephrology - Hypertension-K/P Transplant Weekly,” lecturing “Kidney Size During Nephrosenescence.” Mayo Clinic di Rochester (MN), 30.10.2017 - 3.11.2017.

Visiting Professor “Reporting and Standardization of Monoclonal Gammopathy-Associated Renal Lesions.” Department of Medicine Nephrology and Hypertension Research – Mayo Clinic – Rochester, Minnesota. 7-10.6.2019.

Teaching activities and Ph.D. supervision

Director, Post Graduate Program in Nephrology, University of Cagliari, IT

Full Professor, Nephrology, Medical School at the University of Cagliari, IT

Seminars in Nephrology, 1998 to 2004, the School of Specialization in Paediatrics, University of Cagliari

Supervisor of numerous degree theses in Nephrology

Tutoring activities for numerous undergraduate, postgraduate, and graduate students.

EDUCATION AND TRAINING

Degree in Medicine and Surgery - University of Cagliari, 1982, grade 110/110 and laude.

Registered to Ordine dei Medici – Medical license n. 4368 - 16 Dec 1982

MOTHER TONGUE

Italian

OTHER LANGUAGES

English

- **Reading skills** **Good**
- **Writing skills** **Good**
- **Verbal skills** **Good**

MAIN LINES OF RESEARCH

- 1) HLA and genetics Glomerulonephritis, with proposed regional program of study in collaboration with the Chair of Medical Genetics, University of Sassari, headed by Prof. Francesco Cucca and nephrology and dialysis centers throughout the island
- 2) immunosuppressive therapy of glomerulonephritis
- 3) Cardiovascular risk factors in patients with renal disease, dialysis and transplant recipients during the admission to a renal unit
- 4) Renal Histopathology
- 5) Collaborative study on the polymorphisms of complement in the course of renal transplant patients with reference to the regional center for organ transplantation by Prof. Carlo Carcassi.
- 6) Research program n. ME.P07.006 "Use of the peculiar characteristics of the Sardinian population for the study of quantitative and phenotypic traits of biomedical interest" order activity module "Study of the whole transcriptome and its correlation with the genetic and phenotypic structure" with consequent study epidemiological and genetic on chronic kidney diseases. - National Research Center - INN-CNR-IRGB Association Provision. 05/02/2014.
- 7) AKI and critical care

ACTIVITY IN COLLABORATION WITH OTHER INSTITUTIONS

- 1) Department of Medical Genetics, University of Sassari
- 2) Institute of Neurogenetics and Neuropharmacology, CNR, Cagliari
- 3) Renal Unit of the "Guy's Hospital" in London, Professor Steven Sacks
- 4) Institute of Pathology, Hospital "S. Michele "AOB" G. Brotzu "of Cagliari.
- 5) Institute of Nephrology and Hypertension of Mayo Clinic of Rochester (USA)
- 6) Prof. Dario Roccatello - Centro Ricerche di Immunopatologia e Malattie RARE TORINO
- 7) Prof. Claudio Ronco San Bortolo Hospital Vicenza (IRRIV) .

SCIENTIFIC COMMITTEES

- 1) The editorial board of BMC Nephrology/Journal of Nephrology
- 2) To the Board of Referees of the ERA-EDTA Congress
- 3) Chairman of the international meeting "International Renal Meeting with Mayo Clinic in Sardinia.

I have participated as a Speaker in over 200 meetings with about 100 publications.

RESEARCH (2013-2021).

Genetic study of chronic kidney disease (CKD) Advanced (CKD stages 3b-IV and V, Dialysis and Transplantation), epidemiological evaluation of the prevalence and risk factors for kidney disease.

I have participated as PRINCIPAL INVESTIGATOR in several clinical studies conducted according GCP guidelines (2009-2020).

The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease (NEFIGAN). ClinicalTrials.gov Identifier: NCT01738035.

A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism”. (AMG 416).

A phase 2, double-blind randomized placebo controlled study to evaluate the efficacy and safety of ASP8232 as add-on therapy to angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) in reducing albuminuria in patients with type 2 diabetes and chronic kidney disease. (ALBUM).

Mabthera Drug Utilisation Study and patient alert card evaluation in non oncology patients in Europe: an infusion centre-based approach. BA28478 (ROCHE).

A phase 3, randomized, open-label active-controlled parallel-group multi-center study in non dialysis subjects with anemia associate with chronic kidney disease to evaluate the safety and efficacy of GSK1278863 compared to rhEPO (darbepoetin alfa). 2013-002682-19. GLAXO SMITH KLINE.

A randomized multicenter double blind parallel placebo controlled study of the effects of study drug on renal outcomes in type 2 diabetic subjects with nephropathy. M11-325 . Phase 3. SONAR. AbbVie.

A randomized double blind placebo controlled parallel group multicenter event driven phase III study to investigate the efficacy and safety of finerenone in addition to standard of care on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. Finerenone/ BAY 94-8862 – FIDELIO-DKD. BAYER.

A randomized double blind placebo controlled parallel group multicenter event driven phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. Finerenone/ BAY 94-8862 – FIGARO-DKD. BAYER.

I have participated as NATIONAL LEADER- PRINCIPAL INVESTIGATOR in several clinical studies conducted according GCP guidelines (2009-2020).

1. 200808: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.

2. 200807: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents

Administrative role and position responsibility

- Director of the Renal Unit - ARNAS G. Brotzu Hospital – Cagliari IT (since 2009).
- Director of the Department of Reproduction, Genitourinary, Diseases Kidney Transplant from 01/04/2018.

o Scientific organizations/Coordination of academic activities

- Board of the Italian Society of Nephrology
- Board of “The ProgeNIA/SardiNIA Project” - IRGB-CNR (present)
- Member of the International Myeloma and Kidney Working Group (IKMG)
- Member (elected) of the Board of the Immunopathology Group of the Italian Society of Nephrology
- President of the Italian Society of Nephrology – Sardinian section
- Member (elected) of the Board –Molecular biology Study Group of the Italian Society of Nephrology
- Member (elected) of the Board – Renal ultrasound Study Group of the Italian Society of Nephrology
- Organizing and scientific committee of International Meetings:
 - "International Congress of Immunointervention in Nephrology"
 - “37° Congresso Nazionale Della Società Italiana di Nefrologia". Cagliari 29.5.1996 – 1.6.1996.
- President and scientific board secretary of International Meetings:
 - “The First International Renal Meeting with Mayo Clinic in Sardinia.” Cagliari, 30.4.2011 – 3.5.2011
 - “The Second International Renal Meeting with Mayo Clinic in Sardinia.” Cagliari, 30.4.2013 – 3.5.2013

- “The Third International Renal Meeting with Mayo Clinic in Sardinia.” Cagliari, 30.4.2015 – 3.5.2015
- “The Fourth International Renal Meeting with Mayo Clinic in Sardinia.” Cagliari 30.4.2017 - 2.5.2017
- “The Fifth International Renal Meeting with Mayo Clinic in Sardinia.” Cagliari 30.4.2019 – 3.5.2019
- “The Sixth International Renal Meeting with Mayo Clinic in Sardinia” Cagliari 29-05-2023 to 02-06-2023
- National leader/Principal investigator for Multicentric clinical trials:
 - 1. 200808: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, an event-driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
 - 2. 200807: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, an event-driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents

Editorial activity

- Associated Editor
 - BMC Nephrology
 - Journal of Nephrology
 - Giornale Italiano di Nefrologia
- Reviewer
 - Journal of Nephrology
 - BMC Nephrology
 - Am. J. Kidney Disease
 - Nephrology, Dialysis, and Transplantation
 - Kidney International
 - Clinical Kidney Journal

Membership of scientific societies

- Member of:
 - Italian Society of Nephrology
 - ERA-EDTA
 - American Society of Nephrology

Funding (current and past)

- Legge Regionale 7 Agosto 2007, N.7 “Promozione della ricerca scientifica e dell’innovazione tecnologica in Sardegna”. TENDER 2016

 Significant career breaks

- Board of the Italian Society of Nephrology (2010-2013)

**I declare that the information in this CV is accurate and truthful.
I authorize the processing of personal data, including sensitive ones, in accordance with the effects of Decree Law 196/2003 for the purposes specified in this notice of application.**